Compare ResMed Inc. (RMD) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tyson Foods, Inc. — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Tyson Foods, Inc. trades at $51.77 (market cap $18.39B). The key difference: ResMed Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays the higher dividend (3.9%). Which is the better fit depends on your goals.
| RMD | TSN | |
|---|---|---|
Market Cap | $31.89B | $18.39B |
Sector | Health | Consumer Staples |
52-Week High | $283.28 | $68.75 |
52-Week Low | $182.82 | $50.72 |
Enterprise Value | $31.24B | $25.66B |
Dividend Yield | 1.19% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Tyson Foods (TSN) trades at $52.28, up 1.67% today, but faces bearish technical signals with the stock trading near key support levels. The company reported mixed quarterly results with two beats and one miss in recent quarters, while maintaining modest profitability with 1.03% net margins. Recent news highlights ongoing fraud investigations and reduced 2026 revenue guidance due to beef segment pressures, creating investor uncertainty despite continued institutional buying interest.
The outlook remains cautious with Wall Street maintaining a $69 price target but technical indicators signaling bearish momentum. Investment opportunity exists in the discounted valuation (P/S 0.33) if operational improvements materialize, though risks include ongoing legal scrutiny, commodity price volatility, and execution challenges in the beef business that could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
